Abstract：OBJECTIVE To explore the distribution characteristics of chemotherapy drug-related single nucleotide polymorphisms(SNPs) in cancer patients in our hospital, and to provide the clinical reference for clinical pharmacists to guide the individualized therapy of cancer patients based on SNPs. METHODS Fluorescence-labelled specific probes were used to detect drug-related genes by fluorescence in situ hybridization. The drug-related SNPs of cancer patients from Apr 2016 to Dec 2018 in Peking University Cancer Hospital were retrospectively analyzed. SPSS24.0 software was used to statistically analyze the difference in the frequency distribution of alleles and genotypes, and the Hardy-Weinberg equilibrium test. The distribution characteristics of related gene loci in cancer patients in our hospital regarding the genotype frequency of different populations were studied. RESULTS A total of 17 chemotherapy drug-related gene loci were detected in 2 554 patients. CYP2D6(100C>T) and ABCB1(2677T>G) were not consistent with Hardy-Weinberg equilibrium, while the remaining 15 loci were in Hardy-Weinberg equilibrium. The allele frequencies of DPD, CYP2D6 and UGT1A1 of the Chinese population are significantly different from those of foreign population, which are consistent with internal reports. CONCLUSION The distribution of chemotherapy drug-related SNPs in Chinese tumor patients performs its characteristics. Clinical pharmacists should provide individualized medication advisements according to chemotherapy drug-related SNPs. Based on the application of pharmacogenomics, while referring to international databases such as PharmGKB, the interpretation of SNPs of the Chinese population should be combined with the characteristics of the Chinese population, and the database of the different population cannot be fully referenced.
马旭, 刘颖, 李然, 张关敏, 白羽, 史蕤, 赵冰清, 张艳华. 肿瘤患者化疗药物相关单核苷酸多态性分布分析[J]. 中国药学杂志, 2020, 55(8): 656-662.
MA Xu, LIU Ying, LI Ran, ZHANG Guan-min, BAI Yu, SHI Rui, ZHAO Bing-qing, ZHANG Yan-hua. Analysis of Distribution of Chemotherapy Drug-Related Single Nucleotide Polymorphisms in Cancer Patients. Chinese Pharmaceutical Journal, 2020, 55(8): 656-662.
CAI W M. Pharmacogenomics and individualized medicine [J]. Chin Pharm J(中国药学杂志), 2007, 42(24):1841-1844.
Pharm GKB. A worldwide resourse for pharmacogenomic information[J]. Wiley Interdiscip Rev Syst Biol Med, 2018,10(4):e1417.
WENG H, JIANG M, QIU C F, et al. Hardy-Weinberg equilibrium in Meta-analysis of genetic association study[J]. Chin J Evid Based Cardiovasc Med(中国循证心血管医学杂志), 2016, 8(11):1281-1283.
Beijing Municipal People's Government. Beijing hygiene and population health report 2017[R]. 2017.
BAKER S D, DIASIO R B, O'REILLY S, et al. Phase I and pharmacologic study of oral 5-fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil[J]. J Clin Oncol, 2000,18(4):915-926.
LEE N H. Pharmacogenetics of drug metabolizing enzymes and transporters:effects on pharmacokinetics and pharmacodynamics of anticancer agents[J]. Anticancer Agents Med Chem, 2010, 10(8):583-592.
PAPANASTASOPOULOS P, STEBBING J. Molecular basis of 5-fluorouracil-related toxicity:lessons from clinical practice[J]. Anticancer Res, 2014, 34(4):1531-1535.
LI J, LI J H, CAI J P. Survey of the polymorphism of dihydropyrimidine dehydrogenase gene in the Han nationality population[J]. J China Japan Friendship Hosp(中日友好医院学报), 2005, 19(4):202-207.
WEN D, WANG X, ZHANG M, et al. Frequency detection of the known DPYD alleles in the studied subjects using oligonucleotide microarray[J]. Prog Biochem Biophy, 2004, 31(11):1031-1037.
WEI X, ELIZONDO G, SAPONE A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene[J]. Genomics, 1998, 51(3):391-400.
WEI X, MCLEOD H L, MCMURROUGH J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity[J]. J Clin Investig, 1996, 98(3):610-615.
IACHETTA F, BONELLI C, ROMAGNANI A, et al. The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy[J]. Br J Cancer, 2019, 120(8):834-839.
SHITARA K, MURO K, ITO S, et al. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer[J]. Cancer Epidem Prevent Biom, 2010, 19(5):1311-1319.
ETIENNE-GRIMALDI M C, MILANO G, MAINDRAULT-GBEL F, et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients[J]. Br J Clin Pharm, 2010, 69(1):58-66.
ZHU Y T, ZHANG Q, TANG X S, et al. Relationship between polymorphism of MTHFR and curative effect of adjuvant chemotherapy in postoperative colorectal cancer patients [J]. Chin Pharm J(中国药学杂志), 2017, 52(18):1644-1648.
ZHENG J Q, WANG Q, YANG X, et al. Research progress in toxic effects of antitumor drugs mediated by drug metabolism enzymes and isoforms [J]. Chin Pharm J(中国药学杂志), 2017, 52(13):1115-1119.
BAI Y, WU H W, MA X, et al. Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy[J]. Onco Targets Ther, 2017, 10(4):3071-3081.
FURMAN K D, GRIMM D R, MUELLER T, et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics[J]. Pharmacogenet Genom, 2004, 14(5):279-284.
TAO E X, LIU Z L, CHEN B, et al. Cytochrome P4502D6 gene polymorphism in Chinese population[J]. Chin J Med Gene(中华医学遗传学杂志), 1998, 15(1):34-37.
EAP C B, BROLY F, MINO A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations[J]. J Clin Psychopharmacol, 2001, 21(2):229-234.
SACHSE C, BROCKMOÖLLER J, BAUER S, et al. Cytochrome P450 2D6 variants in a caucasian population:allele frequencies and phenotypic consequences[J]. Am J Hum Genet, 1997, 60(2):284-295.
NCCN Clinical Practice Guidelines in Oncology-Breast Cancer (2019 Version I)[DB/OL]. Fort weshington: NCCN, 2019 [2019-03-14]. http://www.nccn.org/professionals/physicion_gls/f_guidelikes.asp.